DD

Dr. Dmitrij Hristodorov

General Partner at Forbion

Munich, Bavaria

Overview 

Dr. Dmitrij Hristodorov is currently the General Partner at Forbion in Munich, Bavaria, with a strong background in life sciences and extensive experience in business development. He has held leadership roles and served on the board of multiple biotechnology companies, showcasing his expertise in ophthalmology, immunology, and cancer research within the pharmaceutical industry. Dr. Hristodorov's career highlights include his progression from Senior Associate to General Partner at Forbion, demonstrating his strategic leadership and investment acumen, as well as his involvement in various biotechnology companies as a board member, indicating his significant contributions to the growth and development of emerging life science ventures.

Work Experience 

  • General Partner

    2024 - Current

  • Partner

    2021 - 2024

  • Principal

    2021 - 2021

  • Senior Associate

    2020 - 2020

  • Board Member

    2024

  • Board Member

    2024

  • Board Member

    2022

  • Board Member

    2023

  • Board Member

    2022

    New gene editing platform based on recombinases

  • Board Member

    2021

    Targeting RyR1/2 to treat cardiac, musculoskeletal and neurological diseases.

  • Board Member

    2023 - 2025

Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.

Raised $85,000,000.00 from HealthCap, RA Capital Management, Forbion Capital Partners and OrbiMed.

  • Board Member

    2021 - 2024

    One treatment a year. Life changing.

Articles About Dr. Dmitrij

Relevant Websites